(E)-2,2'-((4-hydroxyphenyl)methylene)bis(4-((E)-(5-methyl-1H-tetrazol-1-ylimino)methyl)phenol) | 235106-62-4

• 物质功能分类: 原料药 - 抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (E)-2,2'-((4-hydroxyphenyl)methylene)bis(4-((E)-(5-methyl-1H-tetrazol-1-ylimino)methyl)phenol)
• 英文别名: 2-[[2-hydroxy-5-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenol
• CAS: 235106-62-4
• 化学式: C₂₅H₂₂N₁₀O₃
• 分子量: 510.5
• InChiKey: BLUJRJMLDHEMRX-BMNRKXRESA-N

物化性质

• 熔点：
  >225°C (dec.)
• 沸点：
  816.7±75.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)
• 溶解度：
  碱性溶液（微溶），DMSO（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  173
• 氢给体数：
  3
• 氢受体数：
  11

制备方法与用途

生物活性

体外研究显示，VP 14637对75种RSV A和B亚型的临床分离株具有抗病毒活性。

用途

VP-14637是一种融合抑制剂，临床前研究证明它可以有效阻断RSV感染。

反应信息

• 作为产物：
  描述：

  5-甲基-1-氨基四氮唑 、 4,4'-dihydroxy-3,3'-(4-hydroxyphenyl)methylenebisbenzaldehyde 在 5-甲基-1-氨基四氮唑 作用下， 生成 (E)-2,2'-((4-hydroxyphenyl)methylene)bis(4-((E)-(5-methyl-1H-tetrazol-1-ylimino)methyl)phenol)
  参考文献：
  名称：

  Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases

  摘要：

  本发明提供了用于预防和治疗由Pneumovirinae亚科Paramyxoviridae病毒引起的感染及与此类感染相关的疾病的化合物、组合物和方法。

  公开号：

  US06495580B1

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2020252396A1

  公开（公告）日：2020-12-17

  Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral RSV F protein (e.g., Presatovir, MDT 637, JNJ 179, or an analog thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., RSV infections).

  用于治疗病毒感染的组合物和方法包括含有病毒RSV F蛋白抑制剂（例如Presatovir、MDT 637、JNJ 179或其类似物）的共轭物，连接到一个Fc单体、一个Fc结构域和Fc结合肽、一种白蛋白蛋白质或白蛋白结合肽。特别是，这些共轭物可以用于治疗病毒感染（例如RSV感染）。
• COMBINATION PRODUCTS FOR THE TREATMENT OF RSV
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：EP3892273A2

  公开（公告）日：2021-10-13

  The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1-cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2-ethylsulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2-one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]nonan-2-yl)nicotinamido)benzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide, and 4-amino-8-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-6,6-dimethyl-2-(4-methyl-3-nitrophenyl)-3H-imidazo[4,5-h]isoquinoline-7,9(6H,8H)-dione , for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and one or more Compound B, a pharmaceutical product comprising Compound A and one or more Compound B, the use of the combination of Compound A and one or more of Compound B - or the pharmaceutical product comprising Compound A and one or more Compound B - for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and one or more Compound B in an effective amount to said subject.

  本发明涉及 RSV 抑制化合物 A 的组合，即3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one,和一种或多种 RSV 抑制性化合物 B，选自利巴韦林、GS-5806、MDT-637、BTA-9881、BMS-433771、YM-543403、A-60444、TMC-353121、RFI-641、CL-387626、MBX-300、AZ-27、MEDI8897、CR9501、帕利维珠、Palivizum、CR9501, palivizumab, 3-(5-氯-1-[3-(甲磺酰)丙基]-1H-苯并咪唑-2-基}甲基)-1-环丙基-1,3-二氢-2H-咪唑并[4,5-c]吡啶-2-酮、3-[[7-chloro-3-(2-ethylsulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2-one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]壬烷-2-基)烟酰胺基)苯甲酰基)-5,6-二氢-4H-苯并[b]噻吩并[2,3-d]氮杂卓-2-甲酰胺，以及 4-氨基-8-[3-[[2-(3,4-二甲氧基苯基)乙基]氨基]丙基]-6、6-二甲基-2-(4-甲基-3-硝基苯基)-3H-咪唑并[4,5-h]异喹啉-7,9(6H,8H)-二酮，用于治疗或改善 RSV 感染。本发明进一步涉及化合物 A 和一种或多种化合物 B 的组合物、包含化合物 A 和一种或多种化合物 B 的药物产品、化合物 A 和一种或多种化合物 B 的组合物--或包含化合物 A 和一种或多种化合物 B 的药物产品--用于治疗 RSV 感染的用途，以及治疗或改善有需要的受试者 RSV 感染的方法，该方法包括向所述受试者施用有效量的化合物 A 和一种或多种化合物 B 的组合物。
• Combination products for the treatment of RSV
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US10363253B2

  公开（公告）日：2019-07-30

  The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl) 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1 cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2 ethyl-sulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2 one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]nonan-2 yl)nicotinamido)benzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide, and 4-amino-8-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-6,6-dimethyl-2-(4-methyl 3-nitrophenyl)-3H-imidazo[4,5-h]isoquinoline-7,9(6H,8H)-dione, for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and one or more Compound B, a pharmaceutical product comprising Compound A and one or more Compound B, the use of the combination of Compound A and one or more of Compound B—or the pharmaceutical product comprising Compound A and one or more Compound B—for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and one or more Compound B in an effective amount to said subject.

  本发明涉及 RSV 抑制化合物 A 的组合，即3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl) 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one,和一种或多种 RSV 抑制化合物 B，选自利巴韦林、GS-5806、MDT-637、BTA-9881、BMS-433771、YM-543403、A-60444、TMC-353121、RFI-641、CL-387626、MBX-300、AZ-27、MEDI8897、CR9501、帕利珠单抗，3-(5-氯-1-[3-(甲磺酰)丙基]-1H-苯并咪唑-2-基}甲基)-1-环丙基-1,3-二氢-2H-咪唑并[4,5-c]吡啶-2-酮、3-[[7-chloro-3-(2 ethyl-sulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2 one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]壬烷-2-基)烟酰胺基)苯甲酰基)-5,6-二氢-4H-苯并[b]噻吩并[2,3-d]氮杂卓-2-甲酰胺，以及 4-氨基-8-[3-[[2-(3,4-二甲氧基苯基)乙基]氨基]丙基]-6、6-二甲基-2-(4-甲基-3-硝基苯基)-3H-咪唑并[4,5-h]异喹啉-7,9(6H,8H)-二酮，用于治疗或改善 RSV 感染。本发明进一步涉及化合物 A 和一种或多种化合物 B 的组合物、包含化合物 A 和一种或多种化合物 B 的药物产品、化合物 A 和一种或多种化合物 B 的组合物或包含化合物 A 和一种或多种化合物 B 的药物产品用于治疗 RSV 感染的用途，以及治疗或改善有需要的受试者 RSV 感染的方法，该方法包括向所述受试者施用有效量的化合物 A 和一种或多种化合物 B 的组合物。
• Combination pharmaceutical agents as RSV inhibitors
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10881666B2

  公开（公告）日：2021-01-05

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及向受试者联合或系列施用治疗呼吸道合胞病毒（RSV）感染的药剂，其中治疗包括施用一种有效抑制 RSV 功能的化合物和另外一种或多种具有抗 RSV 活性的化合物组合。
• COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES
  申请人：MicroDose Therapeutx, Inc.

  公开号：US20150209328A1

  公开（公告）日：2015-07-30

  The present invention provides novel crystalline polymorphic forms of MDT-637, in particular, crystalline polymorphic forms with physicochemical properties specifically suited for drug production, amorphous formation, composite form, and methods of preparation thereof. The novel polymorphs described herein are useful for the treatment of respiratory disease, such as disease caused by respiratory syncytial virus.